imo, the data readouts for phase 2 studies only provide enough for a short term hype and consequent pump of the share price. January ‘21 is a classic example of this.
it’s worth trading, if that’s your thing, but a phase 2 data readout would not result in a sustained re-rate.
only revenue and profit will allow us to rerate on a more permanent basis.
all in my opinion, of course.
Is BOT another CSL?, page-14
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $654.2M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 34.5¢ | $2.959M | 8.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 74186 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 422090 | 8 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |